Sarepta Therapeutics (SRPT) Tops Q2 EPS by 45c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($0.46), $0.45 better than the analyst estimate of ($0.91). Revenue for the quarter came in at $35 million versus the consensus estimate of $22.38 million.

Guidance:

Raises FY2017 guidance to $125-130 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• KB Home (KBH) Tops Q3 EPS by 16c
• Franklin BSP Realty Trust (FBRT) Reiterated at Market Outperform by Citizens
• Jefferies Starts China Oilfield Services (2883:HK) (CHOLF) at Buy